Patents by Inventor Nuria Tubau-Juni

Nuria Tubau-Juni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230192652
    Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Application
    Filed: January 13, 2023
    Publication date: June 22, 2023
    Applicant: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Publication number: 20230128450
    Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 27, 2023
    Applicant: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
  • Patent number: 11597717
    Abstract: Provided are compounds of Formula Y-Z: The compounds target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: March 7, 2023
    Assignee: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Patent number: 11548885
    Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: January 10, 2023
    Assignee: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
  • Publication number: 20220089586
    Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
    Type: Application
    Filed: September 20, 2021
    Publication date: March 24, 2022
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Nuria Tubau-Juni, Raquel Hontecillas
  • Publication number: 20220017488
    Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 20, 2022
    Applicant: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Patent number: 11180473
    Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 23, 2021
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Publication number: 20210309635
    Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Application
    Filed: March 25, 2021
    Publication date: October 7, 2021
    Applicant: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni